Cargando…

The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China

BACKGROUND: Data on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aorti...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Xiaoke, Pan, Xiangbin, Zhang, Gejun, Jiang, Zhengming, Liu, Xianbao, Song, Guangyuan, Li, Yi, Wang, Yan, Luo, Jianfang, Tang, Yida, Yuan, Yiqiang, Wu, Yongjian, Ma, Xiang, Zhu, Dan, Zhong, Yucheng, Zhang, Changdong, Dong, Nianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293831/
https://www.ncbi.nlm.nih.gov/pubmed/37383702
http://dx.doi.org/10.3389/fcvm.2023.1064255
_version_ 1785063072457555968
author Shang, Xiaoke
Pan, Xiangbin
Zhang, Gejun
Jiang, Zhengming
Liu, Xianbao
Song, Guangyuan
Li, Yi
Wang, Yan
Luo, Jianfang
Tang, Yida
Yuan, Yiqiang
Wu, Yongjian
Ma, Xiang
Zhu, Dan
Zhong, Yucheng
Zhang, Changdong
Dong, Nianguo
author_facet Shang, Xiaoke
Pan, Xiangbin
Zhang, Gejun
Jiang, Zhengming
Liu, Xianbao
Song, Guangyuan
Li, Yi
Wang, Yan
Luo, Jianfang
Tang, Yida
Yuan, Yiqiang
Wu, Yongjian
Ma, Xiang
Zhu, Dan
Zhong, Yucheng
Zhang, Changdong
Dong, Nianguo
author_sort Shang, Xiaoke
collection PubMed
description BACKGROUND: Data on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aortic valve and tricuspid aortic valve stenosis. METHODS: We analyzed the patient characteristics, procedural features and procedural outcomes of the first 438 patients (223 for bicuspid aortic valve and 215 tricuspid aortic valve) from 21 provinces in 74 sites treated with the SAPIEN 3 valve system for transcatheter aortic valve replacement between September 2020 and May 2022. RESULTS: Procedural mortality was 0.7%. 5 cases during the operation were converted to surgery. Among 438 cases, permanent pacemaker implantation was performed in a total of 12 cases (2.7%). The patient had severe leaflet calcification of the aortic valve, with moderate and severe calcification reaching 39.7% and 35.2% respectively. The size of the implanted valves was predominantly 26 mm and 23 mm, reaching 42.5% and 39.5% respectively. The incidence of moderate or severe perivalvular leak in the postoperative period was 0.5%, with a predominance of 90/10 and 80/20 valve deployment height. There was a significant difference in the deployment height of the valve between bicuspid aortic valve and tricuspid aortic valve, with the bicuspid aortic valve having a more deployment height of 90/10. Annulus size in bicuspid aortic valve group was significantly larger than tricuspid aortic valve group. Valve sizing for oversized, within size, and undersized were different between bicuspid aortic valve and tricuspid aortic valve. CONCLUSIONS: Procedural success rates were high, with similar and good results for bicuspid aortic valve and tricuspid aortic valve, low perivalvular leak for both valve types, and low permanent pacemaker implantation rates for both valve types. Annulus size, valve sizing and coronary artery height were significantly different in the BAV and TAV group.
format Online
Article
Text
id pubmed-10293831
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102938312023-06-28 The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China Shang, Xiaoke Pan, Xiangbin Zhang, Gejun Jiang, Zhengming Liu, Xianbao Song, Guangyuan Li, Yi Wang, Yan Luo, Jianfang Tang, Yida Yuan, Yiqiang Wu, Yongjian Ma, Xiang Zhu, Dan Zhong, Yucheng Zhang, Changdong Dong, Nianguo Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Data on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aortic valve and tricuspid aortic valve stenosis. METHODS: We analyzed the patient characteristics, procedural features and procedural outcomes of the first 438 patients (223 for bicuspid aortic valve and 215 tricuspid aortic valve) from 21 provinces in 74 sites treated with the SAPIEN 3 valve system for transcatheter aortic valve replacement between September 2020 and May 2022. RESULTS: Procedural mortality was 0.7%. 5 cases during the operation were converted to surgery. Among 438 cases, permanent pacemaker implantation was performed in a total of 12 cases (2.7%). The patient had severe leaflet calcification of the aortic valve, with moderate and severe calcification reaching 39.7% and 35.2% respectively. The size of the implanted valves was predominantly 26 mm and 23 mm, reaching 42.5% and 39.5% respectively. The incidence of moderate or severe perivalvular leak in the postoperative period was 0.5%, with a predominance of 90/10 and 80/20 valve deployment height. There was a significant difference in the deployment height of the valve between bicuspid aortic valve and tricuspid aortic valve, with the bicuspid aortic valve having a more deployment height of 90/10. Annulus size in bicuspid aortic valve group was significantly larger than tricuspid aortic valve group. Valve sizing for oversized, within size, and undersized were different between bicuspid aortic valve and tricuspid aortic valve. CONCLUSIONS: Procedural success rates were high, with similar and good results for bicuspid aortic valve and tricuspid aortic valve, low perivalvular leak for both valve types, and low permanent pacemaker implantation rates for both valve types. Annulus size, valve sizing and coronary artery height were significantly different in the BAV and TAV group. Frontiers Media S.A. 2023-06-13 /pmc/articles/PMC10293831/ /pubmed/37383702 http://dx.doi.org/10.3389/fcvm.2023.1064255 Text en © 2023 Shang, Pan, Zhang, Jiang, Liu, Song, Li, Wang, Luo, Tang, Yuan, Wu, Ma, Zhu, Zhong, Zhang and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Shang, Xiaoke
Pan, Xiangbin
Zhang, Gejun
Jiang, Zhengming
Liu, Xianbao
Song, Guangyuan
Li, Yi
Wang, Yan
Luo, Jianfang
Tang, Yida
Yuan, Yiqiang
Wu, Yongjian
Ma, Xiang
Zhu, Dan
Zhong, Yucheng
Zhang, Changdong
Dong, Nianguo
The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
title The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
title_full The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
title_fullStr The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
title_full_unstemmed The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
title_short The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China
title_sort first clinical data of the sapien 3 aortic valve in the treatment of aortic stenosis in china
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293831/
https://www.ncbi.nlm.nih.gov/pubmed/37383702
http://dx.doi.org/10.3389/fcvm.2023.1064255
work_keys_str_mv AT shangxiaoke thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT panxiangbin thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhanggejun thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT jiangzhengming thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT liuxianbao thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT songguangyuan thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT liyi thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT wangyan thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT luojianfang thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT tangyida thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT yuanyiqiang thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT wuyongjian thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT maxiang thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhudan thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhongyucheng thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhangchangdong thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT dongnianguo thefirstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT shangxiaoke firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT panxiangbin firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhanggejun firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT jiangzhengming firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT liuxianbao firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT songguangyuan firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT liyi firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT wangyan firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT luojianfang firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT tangyida firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT yuanyiqiang firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT wuyongjian firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT maxiang firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhudan firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhongyucheng firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT zhangchangdong firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina
AT dongnianguo firstclinicaldataofthesapien3aorticvalveinthetreatmentofaorticstenosisinchina